UCB recently announced that the US Food and Drug Administration (FDA) has approved a label extension for the company's anti-epileptic drug (AED) Vimpat (lacosamide) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients aged ≥4 years. UCB is headquartered in Atlanta, GA, and Brussels, Belgium.
Indications: This new approval provides clinicians with the option to prescribe Vimpat to their pediatric patients either as an oral solution or a convenient tablet, allowing for flexible administration options, an important consideration when treating children.
Dosage/administration: For pediatric patients from 4 years to <17 years, the recommended dosage is based on body weight and is administered orally twice daily. Increased dosage is based on clinical response and tolerability, and no more frequently than once per week is recommended.
Adverse reactions: Adverse reactions in pediatric patients are similar those of adult patients: diplopia, headache, dizziness, and nausea.
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients. [news release]. Atlanta, GA, and Brussels, Belgium: UCB. November 6, 2017. https://www.prnewswire.com/news-releases/ucbs-vimpat-lacosamide-now-approved-by-fda-to-treat-partial-onset-seizures-in-pediatric-epilepsy-patients-300549924.html. Accessed November 9, 2017.
Must Reads in Epilepsy & Seizures
Can a Modified Ketogenic Diet Reduce Seizures?, Epilepsy Behav; ePub 2019 Mar 10; Roehl, et al
Examining Brain Markers for Late-Onset Epilepsy, Neurology; ePub 2019 Jan 25; Johnson, et al
Hospital Readmission After Seizure Discharge, Neurology; ePub 2018 Dec 21; Blank, et al
Information About SUDEP on YouTube Analyzed, Epilepsy Behav; ePub 2018 Dec 7; Rayi, et al
Unplanned Pregnancy, Fetal Loss, and Epilepsy, JAMA Neurology; ePub 2018 Oct 15; Herzog, et al